← Back to Search

Small Molecule Inhibitor

KRT-232 for Polycythemia Vera

Phase 2
Waitlist Available
Research Sponsored by Kartos Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial is testing a new drug, KRT-232, to treat patients with PV who can't take hydroxyurea or who have tried interferon. The trial has 2 parts. In the first part, patients will be given different doses and schedules of KRT-232. In the second part, patients will be given KRT-232 or ruxolitinib.

Eligible Conditions
  • Polycythemia Vera

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients with splenomegaly achieving a response at Week 32

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Active Control
Group I: Part B KRT-232 ArmExperimental Treatment1 Intervention
Recommended KRT-232 dose and schedule from Part A
Group II: Part A Arm 4bExperimental Treatment1 Intervention
KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
Group III: Part A Arm 3Experimental Treatment1 Intervention
KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Group IV: Part A Arm 2bExperimental Treatment1 Intervention
KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
Group V: Part A Arm 2Experimental Treatment1 Intervention
KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Group VI: Part A Arm 1Experimental Treatment1 Intervention
KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
Group VII: Part B Ruxolitinib ArmActive Control1 Intervention
Ruxolitinib per approved prescribing label

Find a Location

Who is running the clinical trial?

Kartos Therapeutics, Inc.Lead Sponsor
16 Previous Clinical Trials
2,030 Total Patients Enrolled
3 Trials studying Polycythemia Vera
473 Patients Enrolled for Polycythemia Vera
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top